This is a summary of the European public assessment report (EPAR) for Cuprymina. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cuprymina.
Therapeutic Indication
### Therapeutic indication Cuprymina is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Therapeutic Area (MeSH)
N/AATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
Various diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| copper (64Cu) chloride | N/A | Copper (64Cu) chloride |
EMA Name
Cuprymina
Medicine Name
Cuprymina
Aliases
N/ANo risk management plan link.
